31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Data indicated that participants' needs fluctuated, with 3 key time points of heightened need: dementia diagnosis, in-home care, and transition into residential care. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the absence of disease modifying therapies for dementia, the question rises what the benefits are of an early dementia diagnosis for patients and their caregivers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The QDRS provides a rapid method to determine study eligibility; stage patients in clinical practice; and improve case ascertainment in population studies. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anosognosia in those with Alzheimer's disease is manifested as poor awareness of deficits in iADL and bADL, depressive changes and behavioural disinhibition. 2 key findings →
Participants: 750 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The objectives of this study were to assess whether Teng's modification of the Mini-Mental State Examination (MMSE) improves its performance as a screening test for cognitive impairment and dementia, and to replicate this comparison in French and English language groups, and for differing assumptions concerning the relative importance of false negative and false positive errors. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is a fast growing world-wide epidemic. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Current Care and Support: Four themes emerged: Communication with empathy; Written information valuable but could be overwhelming; Referrals provided but not necessarily followed; A focus on prescribed anti-dementia medications. 5 key findings →
Design: cross-sectional Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Encouragingly, aspects of secondary prevention were identified that may be protective in reducing the incidence of cognitive impairment post-stroke. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants were distributed across various regions of Australia: seven interviews from inner regional Australia, five interviews from outer regional Australia, and twenty-one interviews from metropolitan areas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
"Sundowning syndrome" refers to the evening decline in mental state among cognitively impaired patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper examined the emotional impact of diagnosis disclosure on recently diagnosed people with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cardiovascular and cerebrovascular disorders are the main cause of death and permanent disability worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 563 articles retrieved, 12 met eligibility criteria. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, particularly Alzheimer's Disease, continues to be a significant global health concern, driven by increasing prevalence as the population ages. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundClinician communication at the time of a dementia diagnosis often inadequately addresses patient and caregiver needs. 5 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Human immunodeficiency virus-type 1 (HIV-l) infection is the most common preventable and treatable cause of neurocognitive impairment in individuals under age 50 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Anosognosia is present in a large proportion of patients with mild Alzheimer's disease (AD), and its frequency increases with the progression of the illness. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study explores how older people with dementia and their family caregivers experience the process from diagnosis to follow-up in primary care, what support is needed, what works well and what could be improved. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
People from UK South Asian communities experience barriers to accessing dementia care. 1 key finding →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
GRACE has demonstrated clinical and cost-effectiveness in trial settings, providing a strong foundation for wider implementation. 2 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
M2 C-index 0.682, M3 0.692, M4 0.687. Adding the dyadic mean yielded an estimated ΔC of 0.010 (95% CI -0.003 to 0.024). 4 key findings →
Participants: 1,762 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events